A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease

NCT03466983 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

IBD

Interventions

DRUG: Iron Isomaltoside
DRUG: Ferric Carboxymaltose

Sponsor

Pharmacosmos A/S